

## Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer's Disease

*Preparing Nuclear Medicine and Radiology Specialists for  
New Diagnostic Workflows*

### Target Audience

This activity has been designed to meet the educational needs of radiologists, neuroradiologists, nuclear medicine physicians, and other healthcare professionals involved in the diagnosis and care of patients with Alzheimer's disease.

### Time

1 hour

### Availability


Spring 2024

### Three Reasons to Host This Meeting

1. Expand your ability to interpret amyloid PET, FDG PET, and tau PET scans to facilitate the timely and accurate diagnosis of Alzheimer's disease
2. Improve your ability to recognize patients with early-stage AD who may benefit from anti-amyloid therapies
3. Increase your confidence in your ability to use PET imaging to identify atypical Alzheimer's disease presentations and avoid incorrect diagnoses

Live interactive educational activities for virtual meetings or a combination of in-person and remote learning ensure that your PVI experience includes:

- High-quality content focused on current clinical management in your field
- World-renowned expert faculty
- Easy access—participants join from anywhere
- Smooth, seamless presentations and audience engagement
- CME/CE-certified educational content that is evidence-based and free of commercial influence or bias
- Logistics, speaker, and content management, including the following for virtual meetings: platform set-up and meeting conducted by professional PeerView staff, interactive polling, and live Q&A with expert faculty



To request a meeting or for more information, please contact:

Email: [meetings@PeerView.com](mailto:meetings@PeerView.com) OR Fax: 1.877.380.6639 OR Online: [PeerView.com/Request-a-Meeting](https://www.peerview.com/Request-a-Meeting)

### Co-Chairs

For a complete list of faculty, contact [meetings@PeerView.com](mailto:meetings@PeerView.com). Availability of specific speakers is dependent on their schedules.



**Jonathan E. McConathy, MD, PhD**  
Director, Advanced Imaging Facility  
Director, Division of Molecular Imaging  
and Therapeutics  
Professor of Radiology  
University of Alabama at Birmingham  
Heersink School of Medicine  
Birmingham, Alabama



**Gil Rabinovici, MD**  
Edward Fein & Pearl Landrith  
Distinguished Professor  
Director, UCSF Alzheimer's Disease  
Research Center  
Departments of Neurology, Radiology  
and Biomedical Imaging  
University of California, San Francisco  
San Francisco, California

# Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer's Disease

## *Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows*

### Activity Description

Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis.

It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid and tau PET) in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. Join PeerView for this educational event, where an AD expert will illustrate how to integrate validated and emerging neuroimaging biomarkers into clinical practice to facilitate a timely AD diagnosis. Through a case-based discussion, this live educational workshop will offer learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and will provide practical guidance on effectively and appropriately incorporating these strategies into patient care.


### Educational Objectives

Upon completion of this activity, participants should be better able to:

- Explain the role and importance of PET imaging to facilitate a timely and accurate diagnosis of AD in the era of disease-modifying therapies
- Integrate current and emerging PET tracers into clinical workflows to improve the early detection and diagnosis of AD



### Accreditation, Support, and Credit

 In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


#### Support

This activity is supported by an educational grant from Lilly.

#### Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Physician Assistants

 PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.